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ABSTRACT Methionine metabolism starts with the
formation of S-adenosylmethionine (AdoMet), the
most important biological methyl donor. This reaction
is catalyzed by methionine adenosyltransferase (MAT).
MAT is the product of two different genes: MAT1A,
which is expressed only in the adult liver, and MAT2A,
which is widely distributed, expressed in the fetal liver,
and replaces MAT1A in hepatocarcinoma. In the liver,
preservation of high expression of MAT1A and low
expression of MAT2A is critical for the maintenance of
a functional and differentiated organ. Here we de-
scribe that in cultured rat hepatocytes MAT1A expres-
sion progressively decreased, as described for other
liver-specific genes, and MAT2A expression was in-
duced. We find that this switch in gene expression was
prevented by adding AdoMet to the culture medium.
We also show that in cultured hepatocytes with de-
creased MAT1A expression AdoMet addition markedly
increased MAT1A transcription in a dose-dependent
fashion. This effect of AdoMet was mimicked by
methionine, and blocked by 3-deazaadenosine and
L-ethionine, but not D-ethionine, indicating that the
effect was specific and mediated probably by a meth-
ylation reaction. These findings identify AdoMet as a
key molecule that differentially regulates MAT1A and
MAT2A expression and helps to maintain the differen-
tiated status of the hepatocyte.—Garcı´a-Trevijano,
E. R., Ujue Latasa, M., Victoria Carretero, M., Bera-
sain, C., Mato, J. M., and Avila, M. A. S-Adenosylmethi-
onine regulates MAT1A and MAT2A gene expression in
cultured rat hepatocytes: a new role for S-adenosylme-
thionine in the maintenance of the differentiated status
of the liver. FASEB J. 14, 2511–2518 (2000)
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S-adenosylmethionine (AdoMet) is the most im-
portant methyl donor in cellular metabolism (1, 2).
In mammals AdoMet can be synthesized in all cells of
the organism, however, it is in the liver where most of
the dietary methionine is converted into AdoMet
and where up to 85% of all methylation reactions
take place (3, 4). The first step in methionine
metabolism is catalyzed by methionine adenosyl-
transferase (MAT) (2–5). MAT is the product of two
different genes, MAT1A and MAT2A, which code for
two different enzymes, MATI/III and MATII respec-
tively, with distinct kinetic and regulatory properties
and that display a tissue-specific pattern of expres-
sion (2, 5–8). MAT1A is expressed only in the adult
hepatocyte, whereas MAT2A shows a wider distribu-
tion and is responsible for AdoMet synthesis in
extrahepatic tissues. In addition, MAT2A is ex-
pressed in the regenerating liver (9) and in the fetal
hepatocyte, being replaced by MAT1A on matura-
tion of the organ (10). Interestingly, in hepatocarci-
noma (rat and human-derived liver cancer cell lines
and hepatocellular carcinoma specimens resected
from patients) a similar situation can be found, and
the dedifferentiated cell recovers the fetal pattern
expressing MAT2A in place of MAT1A (11). This
switch in gene expression influences cellular
AdoMet levels and appears to confer a growth advan-
tage to the proliferating and transformed hepatic
cell, probably through the differences in the MATI/
III and MATII isozyme properties (12).
In addition to the neoplastic liver, impaired
AdoMet synthesis has been reported in chronic liver
disorders such as alcoholic and viral cirrhosis, which
in many cases precede the development of hepato-
carcinoma, and in response to several hepatotoxins
(including ethanol, carbon tetrachloride, galac-
tosamine, and acetaminophen) (reviewed in ref 2).
The pathological relevance of impaired AdoMet
production can be inferred from the protective
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effects of exogenously administered AdoMet, as ob-
served in experimental models of liver damage and
in a recently reported clinical trial (2, 13). In addi-
tion, there is extensive evidence showing that liver
carcinogenesis in rodents can be influenced by di-
etary restrictions in nutrients such as choline, methi-
onine, folic acid, and vitamin B12, which compro-
mise the cellular supply of methyl groups in the form
of AdoMet (14). The link between AdoMet availabil-
ity and the preservation of a functional and differen-
tiated liver is further supported by the chemopreven-
tive effects of AdoMet administration on the
development of preneoplastic lesions and hepatocel-
lular carcinoma in models of rat liver carcinogenesis
(15, 16).
All these evidences suggest that the preservation of
an adequate methyl donor availability, and thus
AdoMet levels, is central to the homeostasis of the
liver, of which the pattern of MAT isozyme gene
expression is a hallmark. In an experimental model
of rat hepatocytes in primary culture, we have ad-
dressed the influence of cellular AdoMet contents
on MAT1A and MAT2A expression. A new role for
AdoMet in the maintenance of the differentiated
status of the hepatocyte through the differential
regulation of both genes is proposed.
MATERIALS AND METHODS
Materials
AdoMet, in the stable form of sulfate-p-toluenesulfonate salt
produced by Knoll (Milan, Italy) was provided by Euro-
pharma (Madrid, Spain). All other reagents were of the best
quality commercially available and otherwise stated they were
purchased from Sigma (St. Louis, Mo.).
Isolation and culture of rat hepatocytes
Liver cells were isolated from male Wistar rats (200–250 g) by
collagenase (Gibco-BRL, Paisley, U.K.) perfusion as described
previously (17). Cells were plated onto 60-mm collagen-
coated culture dishes (type I collagen from rat tail; Collabo-
rative Biomedical, Bedford, Mass.) at a density of 3 3 106 cells
per dish. Cultures were maintained in MEM medium (Gibco-
BRL) supplemented with 10% fetal calf serum (Gibco-BRL),
nonessential amino acids (Gibco-BRL), 2 mM glutamine, 50
mM penicillin, and 50 mg/ml streptomycin sulfate (Gibco-
BRL). After 2-h incubation the culture medium was removed
and cultures were refed the same medium with 2.5% fetal calf
serum. Cell viability was measured by trypan blue exclusion,
and no significant differences were observed at any time
between controls and any of the various treatments per-
formed in this study.
Transient transfection of rat hepatocytes in culture
Hepatocytes were seeded as described above in collagen-
coated multiwell dishes (53105 cells per 30-mm well) 12 h
before transfections. Cells were transfected with 5 mg of a
MAT1A promoter-luciferase construct encompassing 1.4 kb
of the 59-flanking region of this gene (nucleotides 21405 to
165) (18), using the TFx50 reagent (Promega) according to
the manufacturer’s instructions. Five micrograms of the b-ga-
lactosidase expression vector pCH110 (Amersham, Little
Chalfont, U.K.) were included as an internal standard of
transfection efficiency. After 24 h, cells were harvested and
luciferase and galactosidase activities were determined as
described (18). Values reported are means of three indepen-
dent experiments performed in duplicate.
Determination of AdoMet levels in cultured hepatocytes
After extensive washing with saline, cells were lysed and
deproteinized with 0.4 M perchloric acid and centrifuged at
12000 g for 30 min at 4°C. Supernatants were analyzed by
reverse-phase high-performance liquid chromatography as
described previously (19).
RNA isolation and Northern blot analysis
Total hepatocyte RNA was isolated by the guanidinium thio-
cyanate method (20). Aliquots (15 mg) of total RNA were
size-fractionated by electrophoresis in a 1% agarose gel under
denaturing conditions. RNAs were then blotted and fixed to
Nytran membranes (Schleicher & Schuell, Keene, N.H.).
Prehybridization and hybridization were performed as de-
scribed previously (21). Rat cDNA probes for MAT1A,
MAT2A, and albumin (22–24) were labeled with [a-32P]dCTP
(Amersham) by random priming. Hybridization with a probe
for 18S rRNA was performed as a loading control. Mem-
branes were then exposed to X-ray films and signals were
quantitated using the Molecular Analyst software (Bio-Rad,
Hercules, Calif.).
Immunoblot analysis
For determination of MATI/III (the product of MAT1A
gene) protein levels (6), hepatocytes were homogenized as
described previously (21). Equal amounts of protein (20 mg)
were subjected to 10% sodium dodecyl sulfate-polyacrilamide
gel electrophoresis. Proteins were electrophoretically trans-
ferred to nitrocellulose membranes. Immunodetection of
MATI/III was performed using a rabbit anti-rat MATI/III
antiserum (25) and a horseradish peroxidase-conjugated
secondary antibody. Blots were developed by enhanced che-
moluminiscence according to manufacturer’s instructions
(Dupont, Boston, Mass.). To demonstrate that the observed
effects were specific and that equal loading of the gels had
been achieved, after immunodetection of MATI/III mem-
branes were stripped and reprobed with an antibody specific
for actin (Calbiochem-Novabiochem, Darmstadt, Germany).
Statistics
Unless otherwise stated, the data are the means 6 se of at
least four independent experiments. Statistical significance
was estimated with Student’s t test. A P value of ,0.05 was
considered significant.
RESULTS
Rat hepatocytes were placed in primary culture and
the levels of MAT1A expression were determined by
Northern blotting at the onset of cultures (t50) and
after 12 h of incubation. In agreement with other
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studies on the expression of liver-specific genes in
cultured hepatocytes (26–28), a sharp reduction in
MAT1A mRNA was observed (Fig. 1A). However, if
AdoMet was added to cultured hepatocytes at t 5 0
and MAT1A mRNA was evaluated 12 h later a clear
dose-dependent protection in the reduction of this
mRNA was observed (Fig. 1A). AdoMet concentra-
tions between 2 and 4 mM resulted in MAT1A mRNA
levels similar to those found in recently isolated
hepatocytes. This effect on MAT1A mRNA resulted
in higher MATI/III protein levels, as determined by
immunoblotting performed on cellular extracts
from hepatocytes cultured for 18 h in the absence or
presence of AdoMet (2 mM) (Fig. 1B). The effect of
AdoMet on MATI/III protein was specific, because
the levels of other cellular proteins such as actin
were not affected by this treatment (Fig. 1B).
We next wanted to know at which level the
AdoMet was acting on MAT1A expression. Steady-
state mRNA levels are controlled through the inter-
play of various mechanisms. These mechanisms gen-
erally include the regulation of gene transcription
and messenger stability. In an initial approach we
tested whether AdoMet was able to reinduce MAT1A
expression after its decay in culture. For this pur-
pose, isolated hepatocytes were cultured for 12 h,
then AdoMet (4 mM) was added to cells and incu-
bation continued for another 12 h. MAT1A mRNA
levels were measured at the onset of cultures (t50),
after the initial 12 h of culture, and after an addi-
tional 12 h of AdoMet treatment. When compared
with control cultures (in the absence of AdoMet), a
sharp induction of MAT1A mRNA levels was ob-
served in response to AdoMet addition (Fig. 2A).
The accumulation of newly synthesized MAT1A
mRNA suggested that the transcription of this gene
could be stimulated in response to AdoMet. Further
support for this hypothesis was obtained by treating
cells with AdoMet in the presence of the transcrip-
tional inhibitor actinomycin D. Under these condi-
tions, the effect of AdoMet was completely blocked
(Fig. 2A). Actinomycin D also prevented the effect of
AdoMet on MAT1A expression when both agents
were added to hepatocytes at the onset of cultures
(t50) (data not shown). Finally, direct evidence of
AdoMet action on MAT1A gene promoter was ob-
tained in transient transfection experiments using a
construct encompassing the reporter gene luciferase
under the control of rat MAT1A 59-flanking region
(18). Luciferase activity in lysates from hepatocytes
transiently transfected with this construct was in-
duced in a dose-dependent fashion in response to
AdoMet treatment (Fig. 2B). In parallel experi-
ments, treatment of hepatocytes with the glucocorti-
coid triamcinolone (1 mM) also resulted in the
activation of MAT1A promoter and the induction of
luciferase activity levels similar to those found with
AdoMet treatment at 2 mM (data not shown). Taken
together, these observations indicated that AdoMet
was promoting MAT1A transcription.
It is known that AdoMet levels are reduced with
time in isolated and cultured rat hepatocytes (17).
We wanted to know whether in our culture condi-
tions the exogenously added AdoMet could restore
the intracellular pool of this compound. In agree-
ment with previous studies on AdoMet uptake by
liver or isolated hepatocytes (29–31), we observed
that intracellular AdoMet levels were threefold
higher than control levels after 5 min of incubation
in the presence of 2 mM and eightfold higher with 4
mM of exogenously added AdoMet (81624
pmol/mg of protein in control vs. 275675 for 2 mM
AdoMet and 6756102 for 4 mM AdoMet). Incuba-
tion for 5 min with 2 mM L-methionine also in-
creased hepatocyte AdoMet concentration ;2.4-
fold.
We were also interested in the molecular mecha-
nisms through which AdoMet could mediate its
effects on MAT1A expression. In this respect, we
observed that L-methionine, the precursor of
AdoMet together with ATP, was able to partially
mimic the AdoMet effect on MAT1A mRNA levels
after 12 h of treatment at a concentration of 2 mM.
However, under the same conditions, the nonme-
tabolizable D-isomer of methionine elicited no re-
sponse (Fig. 3), suggesting that methionine had to
be metabolized to AdoMet to stimulate MAT1A
expression and that dietary methionine may thus
modulate the expression of this gene. Additional
insight into the mechanism of AdoMet action was
Figure 1. Effect of AdoMet on MAT1A
expression in cultured rat hepatocytes.
A) Rat hepatocytes were cultured as de-
scribed in Materials and Methods.
MAT1A mRNA levels were evaluated by
Northern blotting at the onset of cultures
(t50) and after 12 h of incubation in the
absence or presence of different concen-
trations of AdoMet. Blots were hybridized
with an 18S rRNA cDNA probe to dem-
onstrate equal loading. Representative
blots are shown. B) MATI/III protein levels analyzed by Western blotting in rat hepatocytes cultured for 18 h in the absence or
presence of 2 mM AdoMet (upper panel). Blots were also probed with an antibody for actin protein to demonstrate equal
loading and the specificity of the effect of AdoMet (lower panel). Representative blots are shown.
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obtained with two other experimental approaches.
First, when AdoMet treatment was performed in the
presence of 10 mM of the adenosine analog 3-deaza-
adenosine (C3-Ado) (32), the induction of MAT1A
expression was substantially impaired (Fig. 3). C3-
Ado is an inhibitor of S-adenosylhomocysteine hy-
drolase and leads to a significant increase in the
intracellular levels of S-adenosylhomocysteine
(AdoHcy), additionally it can be converted into the
more stable 3-deaza-derivative of AdoHcy (S-3-deaza-
adenosylhomocysteine, C3-AdoHcy) (32). AdoHcy
and C3-AdoHcy are strong inhibitors of methylation
reactions (2, 32). Second, under similar conditions
the simultaneous addition of AdoMet and L-ethi-
onine (2 mM), the ethyl analog of methionine,
resulted in the impairment of AdoMet action (Fig.
3). If instead of L-ethionine cells were treated with
D-ethionine, AdoMet induction of MAT1A expres-
sion was not affected (data not shown). Ethionine is
also a substrate for MATI/III, which converts it into
S-adenosylethionine, a molecule that is only slowly
metabolized further and thus accumulates in the cell
and inhibits AdoMet actions (33, 34).
The overall transcriptional activity of cultured
hepatocytes was not stimulated by AdoMet treatment
in a nonspecific fashion. This was confirmed when
AdoMet effects on another liver-specific gene such as
albumin were tested. In this case, and as previously
reported, albumin expression decayed with time in
culture; however, AdoMet treatment was not able to
prevent it, whereas under the same conditions the
down-regulation of MAT1A mRNA was almost com-
pletely reversed (Fig. 4A, C). As mentioned in the
introduction the progressive decay in the expression
of liver-specific genes such as MAT1A and albumin
observed in cultured hepatocytes is often accompa-
nied by the activation of other genes that are not
normally expressed in this organ. Some of these
genes, such as the uncoupling protein 2 (UCP2) and
the enzyme telomerase, have been proposed to pro-
vide the hepatic cell with metabolic traits that favor a
proliferative phenotype (28, 35, 36). This is sup-
ported by the fact that such genes are also activated
in transformed hepatic cells (28, 36). These observa-
tions led us to examine the expression of MAT2A in
our model of cultured hepatocytes. Interestingly,
Figure 2. Effect of AdoMet on MAT1A transcription in
cultured rat hepatocytes. A) Hepatocytes were cultured for
12 h and then 4 mM AdoMet was added to culture media
(arrow) in the presence or absence of actinomycin D (5
mg/ml) and incubations continued for another 12 h. MAT1A
mRNA levels were determined by Northern blotting in the
absence of AdoMet (F), in AdoMet-treated cells (f) and in
AdoMet plus actinomycin D-treated cells (D). Data are
means 6 se. B) Hepatocytes were transfected with a construct
harboring 1.4 kb of MAT1A promoter coupled to a luciferase
reporter gene as described in Materials and Methods. Lucif-
erase activity was measured in cell lysates of control and
AdoMet-treated hepatocytes after 24 h of incubation. Lucif-
erase activities, normalized for b-galactosidase expression, are
expressed as fold increase with respect to untreated controls.
*P,0.05 with respect to control values. Data are means 6 se
Figure 3. Mechanism of AdoMet regulation of MAT1A expres-
sion. Hepatocytes were treated with 2 and 4 mM AdoMet; 2
mM L-methionine; 2 mM D-methionine; 2 mM L-ethionine; 2
mM AdoMet plus 2 mM L-ethionine; 10 mM C3-Ado; 10 mM
C3-Ado plus 4 mM AdoMet for 12 h and MAT1A mRNA levels
were determined by Northern blotting. *Differences were
statistically significant (P,0.05) with respect to control levels
(control: without AdoMet). **Differences between 2 mM
AdoMet vs. 2 mM AdoMet plus L-ethionine, and 4 mM
AdoMet vs. 4 mM AdoMet plus C3-Ado were statistically
significant (P,0.05). Data are means 6 se.
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MAT2A expression was already elevated 12 h after
hepatocytes were plated (data not shown), and levels
increased significantly after 24 h in culture (Fig. 4B).
More remarkably, when cells were cultured for 24 h
in the presence of AdoMet (4 mM), the induction of
MAT2A expression was completely prevented (Fig.
4B).
DISCUSSION
As we mentioned, an adequate supply of one-carbon
units to the liver is essential for the preservation of its
differentiated functions. When the flow of one-
carbon units is impaired, because severe dietary
restrictions or liver damage, many of the tissue-
specific functions of this organ are compromised
and can be subsequently lost in a transition to a
preneoplastic condition. An early biochemical event
in these situations is the reduced availability of
AdoMet, which may be because of a shortage of its
precursor (as in methionine-choline-deficient diets)
(14), impaired synthesis because of the inactivation
of MATI/III or impaired MAT1A expression, or the
overall derangement of the methionine cycle (2, 7,
11). The beneficial effects of AdoMet administration
in such situations, which include the prevention of
the neoplastic conversion of the liver, further sup-
port the importance of this metabolic pathway and a
role for this compound in the maintenance of liver
functions (2, 13, 15, 16, 29). However, the molecular
mechanisms of these effects of AdoMet are not fully
understood.
The preservation of MAT1A expression, and thus
MATI/III activity, is a fundamental trait of the
healthy and differentiated hepatocyte. Loss of
MAT1A expression accompanies the malignant
transformation of the liver, and its replacement by
the product of MAT2A gene appears to confer a
growth advantage to the transformed cell (12). In
this context, we wanted to know whether cellular
AdoMet levels could influence the expression of the
methionine-metabolizing gene MAT1A. For this pur-
pose, we turned to an experimental model of rat
hepatocytes in primary culture in which this hypoth-
esis could be directly addressed. It has been shown
that cultured hepatocytes tend to lose the expression
of liver-specific genes as a function of time in culture,
reflecting a certain degree of de-differentiation (26,
27). In agreement with these notions, we observe a
progressive reduction in MAT1A mRNA steady-state
levels with culture time. When AdoMet was added to
hepatocytes at the onset of cultures, the decrease in
MAT1A mRNA levels was prevented in a dose-depen-
dent manner. The effect of AdoMet was very potent
and at certain concentrations MAT1A mRNA expres-
sion returned to levels found in recently isolated
hepatocytes. This effect on MAT1A mRNA was also
observed at the protein level and proved to be
specific because the amount of other cellular pro-
teins, such as actin, was not affected.
In our culture conditions, we have observed a
dose-dependent increase in intracellular AdoMet on
addition of this compound to the medium. Because
of the low membrane permeability of AdoMet, high
extracellular concentrations in the culture media
had to be used to increase significantly the intracel-
lular AdoMet content. The increase of intracellular
AdoMet content observed under these conditions is
likely to occur in vivo after feeding a methionine
reach diet. It should be noted that cellular uptake of
exogenous AdoMet is a controversial issue and that
conflicting data can be found in the literature (30,
31, 37). However, even in those studies, in which it
was concluded that AdoMet was not found to be
taken up by cells, when concentrations .200 mM
were used, intracellular levels of AdoMet were in-
creased (31). Thus, it has been proposed that by
Figure 4. MAT1A, albumin, and MAT2A
mRNAs in cultured rat hepatocytes: ef-
fect of AdoMet treatment. A) MAT1A
mRNA levels were reduced after 12 h in
culture (t512 h). This was prevented by
AdoMet (AdoMet 12 h). B) MAT2A ex-
pression was induced with time in culture
(t524 h), this induction was prevented in
the presence of AdoMet (AdoMet t524
h). Blots were hybridized with a probe for
18S rRNA to check for equal loading. C)
Albumin gene expression was examined
in cultured hepatocytes in the absence or
presence of AdoMet. *Differences were
statistically significant (P,0.05) with re-
spect to controls at t 5 0. **Statistically
significant differences (P,0.05) between
AdoMet treated and untreated hepato-
cyte cultures. Representative blots are
shown. Data are means 6 se.
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increasing the extracellular concentrations of
AdoMet above certain levels, the intracellular pool of
this compound can be modulated (37), and such was
our purpose in the present experiments.
Gene expression regulation in mammalian cells
can be achieved at various levels. The two main
processes involved are the modulation of gene tran-
scription and the control of mRNA stability. Under
these premises, we next addressed the mechanisms
that could mediate the effects of AdoMet on MAT1A
mRNA levels. Our observations indicate that AdoMet
effects on MAT1A mRNA levels took place mainly at
the transcriptional level. Several lines of evidence
support this notion. 1) AdoMet effects on MAT1A
mRNA levels were suppressed in the presence of the
transcriptional inhibitor actinomycin D when both
agents were added together at the onset of cultures;
2) AdoMet was able to reinduce MAT1A expression
after 12 h of decay in culture, reaching levels close to
those found in recently isolated hepatocytes; 3) the
reinduction of MAT1A expression was completely
blocked by actinomycin D; and 4) AdoMet was able
to dose-dependently stimulate reporter gene expres-
sion in transient transfection experiments in which
the rat MAT1A promoter coupled to the luciferase
gene was introduced in cultured hepatocytes. The
magnitude of this effect, at 2 mM AdoMet, was
similar to the response elicited by saturating concen-
trations of glucocorticoids, which we have previously
described as potent regulators of MAT1A gene ex-
pression in liver parenchymal cells (38). Although
the identity of the promoter elements and binding
factors responsible for AdoMet effect have not been
identified yet, this observation strongly supports the
activation of MAT1A gene transcription by AdoMet.
The precise mechanisms through which AdoMet
stimulated MAT1A transcription are still not known;
nevertheless, we have performed a series of experi-
ments that suggest the likely involvement of a meth-
ylation reaction. We observed that AdoMet effect on
MAT1A mRNA levels were blunted when cells were
treated in the presence of the adenosine analog
C3-Ado. This compound raises intracellular concen-
trations of AdoHcy and C3-AdoHcy, potent compet-
itive inhibitors of transmethylation reactions (2, 3,
32). Similarly, L-ethionine also interfered with the
effects of AdoMet on MAT1A mRNA. L-Ethionine is
adenylated at the expense of ATP to produce S-
adenosylethionine, a compound that is only slowly
metabolized further (33, 34). S-Adenosylethionine
accumulates in the cell and competes with AdoMet
in transmethylaton reactions (39). The effect of
L-ethionine was mediated through its conversion
into S-adenosylethionine, because the nonmetaboliz-
able isomer, D-ethionine, at the same concentration
did not interfere with AdoMet induction of MAT1A
expression (data not shown). Taken together, these
observations suggest that a methyl transfer reaction
participates in the mechanism of action of AdoMet.
In addition, these data also support the idea that
AdoMet would be acting intracellularly, where
AdoHcy induced by C3-Ado, and S-adenosylethi-
onine are synthesized and accumulated. AdoMet
effects were partially mimicked by L-methionine
treatment of cultured hepatocytes. This effect is
probably mediated through the conversion of this
amino acid to AdoMet, because D-methionine,
which is not a substrate of MATI/III, did not affect
MAT1A expression. In addition, these observations
may contribute to explain the observed elevation in
rat liver MATI/III activity in response to increased
dietary methionine through the enhancement in
MAT1A expression (40, 41).
As mentioned before, and as we observe in the
case of MAT1A, hepatocytes isolated from healthy
livers tend to lose the expression of liver-specific
genes with time in culture (26, 27). Concomitantly, it
has been realized that other genes that are not
normally expressed in the differentiated liver, but
that are activated in hepatocarcinoma cells, become
induced (28, 35, 36). Such genes are thought to
endow the hepatic cell with metabolic traits compat-
ible with a proliferate phenotype (28, 35). Thus, in
this regard it has been proposed that the cultured
hepatocyte reproduces to a certain extent some of
the genetic changes that occur during the neoplastic
conversion of the liver. Our present observation of
MAT2A expression induction in cultured hepatic
cells fits well within this hypothesis. Indeed, MAT2A
expression is induced when normal hepatocytes pro-
liferate after partial hepatectomy (9) and because of
malignant transformation (11, 12, 42). Nevertheless,
what we find more interesting is the inhibition of
MAT2A expression by AdoMet treatment. Thus, in
response to this agent we observe the simultaneous,
although opposed, regulation of MAT1A and
MAT2A expression in the same cell, whereas the
decay in albumin gene expression was not affected.
Although it is possible that AdoMet only prevents
the change in MAT1A/MAT2A gene expression,
without affecting the expression of other genes,
these effects may be relevant to the preservation of
the differentiated status of the hepatocyte regarding
methionine metabolism. Our observations demon-
strate the exquisite specificity of AdoMet effects on
‘hepatocyte gene expression. Additionally, these
data strongly suggest that the maintenance of certain
AdoMet levels can be crucial in preventing changes
in gene expression that may contribute to the devel-
opment of a preneoplastic phenotype. In addition,
our results may contribute to an understanding of
the mechanisms underlying the hepatocarcinogenic
effects of experimental models in which liver
AdoMet levels are persistently reduced, such as me-
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thionine-choline-deficient diets and the administra-
tion of agents such as ethionine and diethylnitro-
samine (14, 16, 39, 43). These novel actions of
AdoMet may also be behind the preventive effect of
this compound in the development of chemically
induced hepatocarcinoma, a model in which
AdoMet administration results in growth inhibition
and the remodeling of preneoplastic lesions (15,
16), and in the inhibition of cellular growth in
AdoMet-treated human hepatocarcinoma cells in
culture (12).
In summary, our present results lead us to propose a
novel role for AdoMet in the specific regulation of liver
gene expression. These novel actions of AdoMet may
open a new scenario in the biological roles played by
this molecule, which now could be regarded also as an
hepatotrophic agent involved in the preservation of the
differentiated status of the hepatocyte, at least regard-
ing one-carbon metabolism.
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